Latest Commercial Expansion News

Proteomics International has locked in a three-year exclusive distribution deal with Healius, leveraging its extensive pathology network to roll out its Promarker® diagnostic tests nationally from FY27.

CONNEQT Health's June quarter saw record consumer revenue growth and a 70% jump in enterprise subscription ARR, supported by a $5.5 million placement and progress on its FDA regulatory pathway for its cloud-based vascular analytics platform.

Telix Pharmaceuticals reported a 21% year-on-year revenue jump to US$247 million in Q2 2026, buoyed by strong Precision Medicine sales and a new Regeneron partnership. The company also secured FDA alignment on a pivotal prostate cancer trial and expanded its manufacturing footprint.

Iondrive appoints ex-BHP innovation chief Dr Grant Caffery as CEO, signalling a pivot from development to commercial scale-up following strong rare earth recovery results and a US$15 million Oklahoma funding pathway.

Klevo Rewards has successfully completed a 14-day commercial trial of its stablecoin transaction platform, generating approximately USD 1.22 million in gross revenue and validating its payment capabilities.

Orthocell Limited has posted record revenue for FY2026, driven by strong sales growth of Remplir™ and Striate+™ products in Australia, the US, and new international markets, supported by a robust $44.1 million cash position.

HitIQ Limited attributes recent share price and volume spikes to a recent $1.4 million private placement and investor buying, denying any undisclosed material information.

ClearVue Technologies has earned three international certifications for its Gen 3 Vision Glass, confirming its photovoltaic performance, safety, and durability across multiple product variants.

Dataworks Group has arranged a $1.5 million unsecured working capital facility with a three-month term and 18% interest, aiming to strengthen liquidity and support ongoing and new commercial contracts without diluting equity.

Orthocell has secured a strategic foothold in Thailand's $84 million nerve repair sector by appointing MediTime as exclusive Remplir distributor, leveraging established clinical networks to accelerate market penetration.

Mesoblast has received a Biologics License Application filing number from the FDA for rexlemestrocel-L, targeting life-threatening bleeding in end-stage heart failure patients with LVADs, advancing its regulatory journey with orphan drug and RMAT designations.

Echo IQ has raised approximately A$110 million through a heavily supported institutional placement to fund its US commercial rollout and speed up development of its AI-driven cardiovascular diagnostics.